OMER News and Press, Omeros Corporation From 11/04/19

Insperity (NYSE: NSP ) -27%  on Q3 results . More news on: Insperity, Inc., Omeros Corporation, Ceragon Networks Ltd., Stocks on the move, Read more ...

-- Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion -- Omeros Corporation (Nasdaq: OMER) today announced that results of a prospective, controlled study showing that its FDA-approved ophthalmic drug OMIDRIA ® (phenylephrine and ketorolac intrao...

Gainers: SOHU   +2.6% . EBR   +2.1% . BAK   +1.5% . XNET   +1.3% . FNKO   +1.3% . More news on: Sohu.com Limited, Centrais Elétricas Brasileiras S.A. - Eletrobrás, Braskem S.A., Stocks on the move, Read more ...

Omeros ( OMER +0.9% ) is up modestly in early trade, albeit on light volume, on the heels of its update on marketing applications for lead candidate narsoplimab (OMS721) for the potential treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). ...

– Includes Deferral for PIP Completion Until After Approval of Marketing Authorization Application – Omeros Corporation (Nasdaq: OMER) today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has issued a positive opinion for the company&...

– Rolling Submission of the Remaining BLA Sections Continues On Track for Scheduled Completion 1H 2020 – Omeros Corporation (Nasdaq: OMER) has submitted the first sections of the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Adm...

ChemoCentryx (NASDAQ: CCXI) develops drugs for orphan diseases, meaning those with fewer than 200,000 patients in the U.S. Currently, ChemoCentryx has four drug candidates in development with the most advanced being avacopan. This quarter, ChemoCentryx will announce pivotal trial results wit...

Omeros Corporation (OMER) is commercial stage pharmaceutical company with one marketed drug - Omidria, one late-stage, and several early-stage drug candidates. Omidria is used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing ...

Omeros Corporation (Nasdaq: OMER) today announced that the product-specific J-code for OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce...

Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria ( i.e. , high levels of plasma proteins in the urine) and inflammation. The...